Overview

Camrelizumab Combined With Neoadjuvant Concurrent Chemoradiotherapy for Resectable Locally Advanced ESCC（NICE-RT）

Status:
Not yet recruiting

Trial end date:
2024-12-25

Target enrollment:

Participant gender:

Summary

NICE-RT study is a "safety run-in" and phase II trial evaluating the safety and efficacy of Camrelizumab combined with Nab-paclitaxel and Carboplatin and Radiotherapy in patients with resectable locally advanced esophageal squamous cell carcinoma.

Phase:

Phase 2

Details

Lead Sponsor:

Shanghai Chest Hospital

Treatments:

Albumin-Bound Paclitaxel
Carboplatin
Paclitaxel